Stockreport

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris 

Biofrontera Inc.  (BFRI) 
PDF • Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promisi [Read more]